title: Monoclonal antibody 12D5 inhibits eosinophil infiltration in the brain of Angiostrongylus cantonensis-infected BALB/c mice.
abstract: Each of BALB/c mice was infected with 50 Angiostrongylus cantonensis larvae. One group of mice received an intraperitoneal injection of 50 μg 12D5 monoclonal antibody (mAb) against a 98 kDa antigen of adult worms at 10 days post-infection (dpi), with a booster injection of 25 μg at 12 dpi. Five mice from each group were sacrificed at 14 dpi for pathological examination and RNA extraction. The infiltration of eosinophils and severity of eosinophilic meningitis were reduced in 12D5 mAb-treated mice compared with the infected mice without 12D5 treatment. The levels of eotaxin mRNA expression in spleen significantly increased and the expression of the Th2-type cytokine IL-5 significantly decreased. However, the expression of IL-4 was not changed. 12D5 mAb can observably enhance the survival rate of infected mice and reduce symptoms of angiostrongyliasis. A. cantonensis infection is a major cause of eosinophilic meningoencephalitis. The results of this study could be helpful for the development of treatment of human angiostrongylosis.
authors.affiliation: Shenzhen Center for Disease Control and Prevention, Shenzhen, Guangdong Province, China.
authors.forename: Jun-Jian
authors.initials: JJ
authors.lastname: Li
authors.forename: Ren-Li
authors.initials: RL
authors.lastname: Zhang
authors.forename: Yu-Cai
authors.initials: YC
authors.lastname: Fu
authors.forename: Wei-ping
authors.initials: WP
authors.lastname: Wu
authors.forename: Mu-Xin
authors.initials: MX
authors.lastname: Chen
authors.forename: Yi-Jie
authors.initials: YJ
authors.lastname: Geng
authors.forename: Da-Na
authors.initials: DN
authors.lastname: Huang
authors.forename: Lin
authors.initials: L
authors.lastname: Ai
authors.forename: Fan
authors.initials: F
authors.lastname: Yang
authors.forename: Zhong
authors.initials: Z
authors.lastname: Hu
mesh_terms: D017185:Angiostrongylus cantonensis / Q000276:immunology / Q000472:pathogenicity*; D000818:Animals; D000909:Antibodies, Helminth / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D001921:Brain / Q000276:immunology / Q000473:pathology*; D054413:Chemokine CCL11 / Q000096:biosynthesis; D004804:Eosinophils / Q000276:immunology*; D005260:Female; D020869:Gene Expression Profiling; D007155:Immunologic Factors / Q000008:administration & dosage*; D007274:Injections, Intraperitoneal; D015847:Interleukin-4 / Q000096:biosynthesis; D015848:Interleukin-5 / Q000096:biosynthesis; D008581:Meningitis / Q000276:immunology / Q000473:pathology / Q000517:prevention & control; D051379:Mice; D008807:Mice, Inbred BALB C; D013154:Spleen / Q000276:immunology; D017206:Strongylida Infections / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016019:Survival Analysis
chemical_list: D000909:Antibodies, Helminth; D000911:Antibodies, Monoclonal; D054413:Chemokine CCL11; D007155:Immunologic Factors; D015848:Interleukin-5; D015847:Interleukin-4